Previous 10 | Next 10 |
Organon (NYSE:OGN) is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance. For the quarter, the topline dipped ~1% YoY to $1.6B aft...
Organon (NYSE:OGN) declares $0.28/share quarterly dividend, in line with previous. Forward yield 3.06% Payable Dec. 16; for shareholders of record Nov. 22; ex-div Nov. 19. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organon declares $0.28 div...
Organon (NYSE:OGN): Q3 Non-GAAP EPS of $1.67 beats by $0.23; GAAP EPS of $1.27 beats by $0.07. Revenue of $1.6B (-0.6% Y/Y) beats by $10M. Press Release For further details see: Organon EPS beats by $0.23, beats on revenue
Third quarter 2021 revenue of $1,600 million Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing operations of $424 million, or $1.67 per diluted share Adjusted EBITDA of $636 million Board of Dir...
Acquisition adds pipeline of candidates targeting novel treatments in women’s health Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug de...
Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is $1.44 and the consensus Revenue Estimate is $1.59B. Organon shares traded ~4% higher after the company swung back to growth with better than&...
Merck fell almost 10% on Friday after Pfizer announced its own antiviral pill. The stock is now up less than 10% after its pre-antiviral announcement levels, offering an attractive entry point. Merck could earn upwards to $1 per share in incremental EPS from its molnupiravir Covid...
NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary Canada NewsWire Public reimbursement is effective on November 10 th . KIRKLAND, QC , Nov. 8, 2021 /CNW/ - Organon (NYSE: OGN) is pleased to ...
FMC Corporation and Sabra Healthcare are the new additions reviewed using FASTgraphs and relating future potential. The complete list of add ons and trims are shown with prices, costs and the resulting effect to Rose portfolio “RIG” 2022 income. The 4 honorable menti...
Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...